ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

ZYME Company Profile and Key Details

NYSE : ZYME

Zymeworks Inc.

$12.00

-0.13-1.07%

At Close 4:00 PM

$12.12

0.12+1.00%

After-Market 03:59 PM

60.77

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

ZYME Stock Price Chart

Stock Price Today

Zymeworks Inc. (ZYME) stock declined over -1.07%, trading at $12.00 on NYSE, down from the previous close of $12.13. The stock opened at $12.21, fluctuating between $11.68 and $12.21 in the recent session.

Stock Snapshot

12.13

Prev. Close

12.21

Open

834.92M

Market Cap

69.58M

Number of Shares

11.675

Day Low

12.21

Day High

-7.41

P/E Ratio

96.72%

Free Float in %

-1.62

EPS (TTM)

6.56

Book Value

-1.73

Cash Flow per Share

691.62K

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 07, 2025	12.21	12.21	11.67	12.00	691.88K
Mar 06, 2025	12.44	12.50	11.68	12.13	1.39M
Mar 05, 2025	12.72	13.18	12.70	13.18	671.46K
Mar 04, 2025	12.50	12.97	12.40	12.75	695.68K
Mar 03, 2025	13.43	13.46	12.46	12.74	705.78K
Feb 28, 2025	13.28	13.69	13.11	13.40	808K
Feb 27, 2025	13.86	14.07	13.30	13.34	321.93K
Feb 26, 2025	14.01	14.01	13.29	13.86	465.8K
Feb 25, 2025	14.04	14.04	13.11	13.57	453.49K
Feb 24, 2025	14.39	14.39	13.85	13.95	272.7K
Feb 21, 2025	14.19	14.41	13.85	14.39	342.9K
Feb 20, 2025	14.72	14.82	13.89	14.02	468.2K
Feb 19, 2025	14.63	14.82	14.50	14.82	318.61K
Feb 18, 2025	15.00	15.25	14.45	14.67	324.13K
Feb 14, 2025	14.73	15.16	14.61	15.01	242.32K
Feb 13, 2025	14.32	14.69	14.23	14.62	280.08K
Feb 12, 2025	13.00	14.34	12.82	14.30	724.13K
Feb 11, 2025	13.94	14.09	13.23	13.25	411.99K
Feb 10, 2025	14.32	14.58	14.07	14.19	280.77K
Feb 07, 2025	14.79	14.96	14.19	14.28	315.53K

Contact Details

Vancouver, BC V5T 1G4

Canada

Website: https://www.zymeworks.comContact: 160 467 81388

About Company

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Frequently Asked Questions

What is the current Zymeworks Inc. (ZYME) stock price?

Zymeworks Inc. (NYSE: ZYME) stock price is $12.00 in the last trading session. During the trading session, ZYME stock reached the peak price of $12.21 while $11.68 was the lowest point it dropped to. The percentage change in ZYME stock occurred in the recent session was -1.07% while the dollar amount for the price change in ZYME stock was -$0.13.

ZYME's industry and sector of operation?

The NYSE listed ZYME is part of Biotechnology industry that operates in the broader Healthcare sector. Zymeworks Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ZYME?

Dr. Ali Tehrani Ph.D.
Advisor
Dr. Ryan Dercho Ph.D.
Senior Director of Corporation Affairs
Nina Weisser Ph.D.
Director of Multispecific Antibody Therapeutics
Dr. Paul Moore Ph.D.
Chief Scientific Officer
Dr. Christopher Astle Ph.D.
Senior Vice President & Chief Financial Officer
Mr. Neil A. Klompas C.A., CPA, CA, CPA
Pres & Chief Operating Officer
Dr. Neil Josephson M.D.
Chief Medical Officer
Jack W. Spinks
Associate Director of Investor Relations
Mr. Kenneth H. Galbraith C.A.
Chief Executive Officer & Chairman
Dr. David Poon Ph.D.
Vice President of Bus. Devel. and Alliance Management
Diana Papove
Senior Mang. of Corporation Communications
Dr. Jeffrey Smith M.D.
Senior Vice President of Early-Stage Devel.
Mr. Mark Hollywood
Executive Vice President and Head of Technical & Manufacturing Operations
Mr. Daniel Dex J.D., Ph.D.
Senior Vice President, Corporation Sec. & Gen. Counsel
Ms. Laura O'Connor
Executive Director & Head of Global HR
Ms. Bijal Desai M.B.A.
Executive Director of Corporation Fin., FP&A & Procurement
Mr. Neil A. Klompas C.A., C.P.A., CA, CPA
Pres & Chief Operating Officer

How ZYME did perform over past 52-week?

ZYME's closing price is 50.56% higher than its 52-week low of $7.97 where as its distance from 52-week high of $17.70 is -32.2%.

How many employees does ZYME have?

Number of ZYME employees currently stands at 294.

Link for ZYME official website?

Official Website of ZYME is: https://www.zymeworks.com

How do I contact ZYME?

ZYME could be contacted at phone 160 467 81388 and can also be accessed through its website. ZYME operates from 114 East 4th Avenue, Vancouver, BC V5T 1G4, Canada.

How many shares of ZYME are traded daily?

ZYME stock volume for the day was 691.62K shares. The average number of ZYME shares traded daily for last 3 months was 484.61K.

What is the market cap of ZYME currently?

The market value of ZYME currently stands at $834.92M with its latest stock price at $12.00 and 69.58M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	294
Beta	1.13
Sales or Revenue	$76.01M
5Y Sales Change%	-0.396%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology